Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Teen drug use remains low, but survey finds small rise in heroin and cocaine use - 2Overseeing Individual budgets Successfully
- 3New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- 4Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- 5Phenomenal Web-based MBA Stages for Proficient Headway
- UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- US FDA unveils new pathway to approve personalized therapies
- Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
- 6 Hints to Upgrade Your Charm, In addition to Your Mentality
- People are getting their news from AI – and it’s altering their views
- Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- The most effective method to Pick a Campervan That Offers Something else for Less
